Globus Medical

GMED · NYSE

$78.96+$3.31 (+4.38%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $75.65

GMED analyst rating

BuyConsensus of 16 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy12
Hold4
Underperform0
Sell0

12-month price target · 17 analysts

Average $105.06 (+33.1% upside)

Low: $84.84
Now: $78.96
High: $131.25

Upgrades and downgrades

The latest rating actions, newest first

GMED analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Oct 1, 2026	Maintains	Outperform	$115.00 → $85.00	57%
Wells Fargo	Aug 7, 2026	Maintains	Overweight	$103.00 → $99.00	54%
UBS	Jul 28, 2026	Initiates	Neutral	$82.00	59%
Truist Securities	Jul 16, 2026	Maintains	Buy	$115.00 → $100.00	50%
RBC Capital	Jul 13, 2026	Maintains	Outperform	$120.00 → $115.00	49%
BMO Capital	Jul 9, 2026	Initiates	Outperform	$94.00	—
Stifel	Jul 8, 2026	Maintains	Hold	$95.00 → $80.00	40%
Piper Sandler	Jun 15, 2026	Maintains	Overweight	$115.00 → $100.00	43%
RBC Capital	May 8, 2026	Maintains	Outperform	$115.00 → $120.00	49%
Wells Fargo	May 8, 2026	Maintains	Overweight	$104.00 → $103.00	54%

The case for and against

Updated Oct 14, 2026

Bull case

Globus Medical is supported by strong fundamentals, with Q1 revenue of $760 million, organic constant-currency growth of 11%, and non-GAAP EPS of $1.12, all well above consensus, underscoring effective execution across musculoskeletal solutions and enabling technologies. Its outlook is reinforced by durable U.S. Spine momentum, 34% trauma growth, a 21% rebound in enabling tech, and a strategic shift toward recurring revenue that should complement the company’s guide of $3.18-$3.22 billion in 2026 sales and $4.70-$4.80 EPS. The company’s best-in-class margin profile, with gross margin at 69.2% and adjusted EBITDA margin at 32.3%, plus debt-free status and $799 million in cash, provides financial flexibility to keep investing in innovation and share gains.

Bear case

Globus Medical is facing a negative fundamental outlook because its core spine and musculoskeletal franchise is exposed to intense competitive pressure from larger device peers such as MDT, SYK, and ZBH, while staffing shortages, pricing pressure, and FX/macro headwinds can further weigh on execution. The company’s merger-related risk is also material: the NuVasive and Nevro integrations may create revenue dis-synergies, commercial disruption, and weaker-than-expected margins, as highlighted by Nevro sales of $83M in 1Q26, down 17% Q/Q, and adjusted EBITDA margin falling to 11.8% from 21.2% in 4Q25. With a bear case calling for revenue growth slowing to the low-single digits and margins staying flat, downside risk remains elevated if Enabling Technologies and post-merger recovery fail to offset pressure in the U.S. and international businesses.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.